Enterprise Value
49.08M
Cash
193.3M
Avg Qtr Burn
-22.93M
Short % of Float
12.86%
Insider Ownership
1.27%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Phase 2 Data readout | |
ADVM-022 (AAV.7m8 Afiblercept) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |